Brazier John
Health Economics and Decision Science and NICE Decision Support Unit, School of Health and Related Research, University of Sheffield, Sheffield, UK.
Pharmacoeconomics. 2008;26(9):769-79. doi: 10.2165/00019053-200826090-00007.
This article reviews the general issues in valuing health states for use in cost-effectiveness analysis and the specific issues considered by the National Institute for Health and Clinical Excellence (NICE) in its recent review of the methods of technology appraisal. The general issues are how to describe health, how to value health and who should provide the values for health. The specific issues considered by NICE included whether and what should be the reference-case instrument, what to do when there are no data using the reference-case measure, what to do when the reference-case measure is not suitable and how to judge when it is not suitable, how to review and synthesize data, and how to incorporate health-state utility values into cost-effectiveness models.
本文回顾了在成本效益分析中评估健康状态所涉及的一般问题,以及英国国家卫生与临床优化研究所(NICE)在其近期技术评估方法审查中所考虑的具体问题。一般问题包括如何描述健康、如何评估健康以及应由谁来提供健康价值。NICE所考虑的具体问题包括参考案例工具是否以及应该是什么、在没有使用参考案例测量数据时该怎么做、参考案例测量不适用时该怎么做以及如何判断其不适用、如何审查和综合数据,以及如何将健康状态效用值纳入成本效益模型。